Zobrazeno 1 - 10
of 869
pro vyhledávání: '"Jack A Roth"'
Autor:
Anirban Maitra, Alexandre Reuben, Chantale Bernatchez, Marie-Andree Forget, Donastas Sakellariou-Thompson, Tina Cascone, Annikka Weissferdt, Jianjun Zhang, Boris Sepesi, Ignacio Wistuba, Ara A Vaporciyan, Marcelo V Negrao, Lorenzo Federico, John V Heymach, Don L Gibbons, Cara L Haymaker, Junya Fujimoto, Jack A Roth, Parin Shah, Peixin Jiang, Roohussaba Khairullah, Yan Long, Shiaw-Yih Lin, Meredith L Frank, Chantal Alexia Neutzler, Chi-Wan B Chow, Kyle Gregory Mitchell, Daniel J McGrail
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/695b65690403434c9d38fde087d200d1
Autor:
Jianhua Zhang, Hao Xu, Alexandre Reuben, Brian Alexander, Jack Lee, Tina Cascone, Jianjun Zhang, Kyle G Mitchell, Marcelo V Negrao, Stephen G Swisher, John V Heymach, Don L Gibbons, Jack A Roth, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Anne Tsao, Chang-Jiun Wu, Vincent A Miller, Bonnie S Glisson, Karthikeyan Murugesan, Meagan Montesion, Garrett Frampton, Katja Schulze, Ilze Bara, Vincent Shen, Sylvia Hu, Dawen Sui, Michael E Goldberg, David S Barreto, Jacqulyne P Robichaux, Carl M Gay, Lingzhi Hong, Waree Rinsurongkawong, Vassiliki Papadimitrakopoulou, Gaurav Singal, Lee A Albacker, David Shames
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. W
Externí odkaz:
https://doaj.org/article/deb634044c5641f5a4d7746a8b39b598
Autor:
Xifeng Wu, Qinchaung Wang, Jianchun Gu, Linbo Wang, David W Chang, Yuanqing Ye, Maosheng Huang, Jack A Roth
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Recent advances in T cell-related immunotherapy have brought remarkable progress in the treatment of non-small cell lung cancer (NSCLC). However, whether and how genetic variations of T cell cancer immune response genes can influence clini
Externí odkaz:
https://doaj.org/article/a8c5ab2cd6ab4a188a9055f497e0529b
Autor:
Franziska Haderk, Yu-Ting Chou, Lauren Cech, Celia Fernández-Méndez, Johnny Yu, Victor Olivas, Ismail M. Meraz, Dora Barbosa Rabago, D. Lucas Kerr, Carlos Gomez, David V. Allegakoen, Juan Guan, Khyati N. Shah, Kari A. Herrington, Oghenekevwe M. Gbenedio, Shigeki Nanjo, Mourad Majidi, Whitney Tamaki, Yashar K. Pourmoghadam, Julia K. Rotow, Caroline E. McCoach, Jonathan W. Riess, J. Silvio Gutkind, Tracy T. Tang, Leonard Post, Bo Huang, Pilar Santisteban, Hani Goodarzi, Sourav Bandyopadhyay, Calvin J. Kuo, Jeroen P. Roose, Wei Wu, Collin M. Blakely, Jack A. Roth, Trever G. Bivona
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alt
Externí odkaz:
https://doaj.org/article/be0a7eca3725431ab19bfe58739629b9
Autor:
Rong Li, Xia Pu, Joe Y Chang, Yuanqing Ye, Ritsuko Komaki, John D Minna, Jack A Roth, Baohui Han, Xifeng Wu
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0150467 (2016)
Severe radiation-induced toxicities limit treatment efficacy and compromise outcomes of lung cancer. We aimed to identify microRNA-related genetic variations as biomarkers for the prediction of radiotherapy-induced acute toxicities. We genotyped 233
Externí odkaz:
https://doaj.org/article/9341571c40dd4b7c89abeea6d90d6eca
Autor:
Bingbing Dai, Shaoyu Yan, Humberto Lara-Guerra, Hiroyuki Kawashima, Ryo Sakai, Gitanjali Jayachandran, Mourad Majidi, Reza Mehran, Jing Wang, B Nebiyou Bekele, Veerabhadran Baladandayuthapani, Suk-Young Yoo, Ying Wang, Jun Ying, Feng Meng, Lin Ji, Jack A Roth
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0123967 (2015)
Expression of the tumor suppressor gene TUSC2 is reduced or absent in most lung cancers and is associated with worse overall survival. In this study, we restored TUSC2 gene expression in several wild type EGFR non-small cell lung cancer (NSCLC) cell
Externí odkaz:
https://doaj.org/article/4b0fbfba8b0c41f0b85418d2f59eecb8
Autor:
Chengcheng Guo, Haibo Lu, Wen Gao, Li Wang, Kaihua Lu, Shuhong Wu, Apar Pataer, Maosheng Huang, Randa El-Zein, Tongyu Lin, Jack A Roth, Reza Mehran, Wayne Hofstetter, Stephen G Swisher, Xifeng Wu, Bingliang Fang
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74973 (2013)
We recently showed that IGFBP2 is overexpressed in primary lung cancer tissues. This study aims to determine whether IGFBP2 is elevated in blood samples of lung cancer patients and whether its level is associated with clinical outcomes.Plasma IGFBP2
Externí odkaz:
https://doaj.org/article/803ef1607e1a448087357c4841b43520
Autor:
Jieru Meng, Mourad Majidi, Bingliang Fang, Lin Ji, B Nebiyou Bekele, John D Minna, Jack A Roth
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77067 (2013)
TUSC2-defective gene expression is detected in the majority of lung cancers and is associated with worse overall survival. We analyzed the effects of TUSC2 re-expression on tumor cell sensitivity to the AKT inhibitor, MK2206, and explored their mutua
Externí odkaz:
https://doaj.org/article/8994cc1801404ca8b0c882f491cd5ba7
Autor:
Charles Lu, David J Stewart, J Jack Lee, Lin Ji, Rajagopal Ramesh, Gitanjali Jayachandran, Maria I Nunez, Ignacio I Wistuba, Jeremy J Erasmus, Marshall E Hicks, Elizabeth A Grimm, James M Reuben, Veerabhadran Baladandayuthapani, Nancy S Templeton, John D McMannis, Jack A Roth
Publikováno v:
PLoS ONE, Vol 7, Iss 4, p e34833 (2012)
Tumor suppressor gene TUSC2/FUS1 (TUSC2) is frequently inactivated early in lung cancer development. TUSC2 mediates apoptosis in cancer cells but not normal cells by upregulation of the intrinsic apoptotic pathway. No drug strategies currently exist
Externí odkaz:
https://doaj.org/article/eb78a39f4a0d4587ba18e50d4d831184
Autor:
Yong He, Zhen Zhou, Wayne L Hofstetter, Yanbin Zhou, Wenxian Hu, Chengcheng Guo, Li Wang, Wei Guo, Apar Pataer, Arlene M Correa, Yiling Lu, Jing Wang, Lixia Diao, Lauren Averett Byers, Ignacio I Wistuba, Jack A Roth, Stephen G Swisher, John V Heymach, Bingliang Fang
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31087 (2012)
Because cell signaling and cell metabolic pathways are executed through proteins, protein signatures in primary tumors are useful for identifying key nodes in signaling networks whose alteration is associated with malignancy and/or clinical outcomes.
Externí odkaz:
https://doaj.org/article/edd86cc5408944bca029b94bd65659cf